23 Feb Bellicum
Rick Fair, President and CEO
Oct. 11 | 4:30pm | Oxford Biomedica Ballroom
Bellicum Pharmaceuticals is a clinical-stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR T cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR T cell products capable of overriding key immune inhibitory mechanisms.